Nanobody-based chimeric receptor gene integration in Jurkat cells mediated by PhiC31 integrase

Experimental Cell Research

Volumn 317, Issue 18, 2011, Pages 2630-2641

  Iri Sofla, Farnoush Jafari ^a   Rahbarizadeh, Fatemeh ^a   Ahmadvand, Davoud ^b   Rasaee, Mohammad J ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chimeric receptor; Nanobody; NLS; PhiC31 integrase

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G3; INTEGRASE; LYMPHOCYTE ANTIGEN RECEPTOR; MUCIN 1; NANOBODY; PHIC31 INTEGRASE; RECOMBINANT RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC TRANSDUCTION; HINGE REGION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; T LYMPHOCYTE;

EID: 80053574967     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.08.015     Document Type: Article

References (45)

1. Hombach A., Heuser C., Abken H. The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr. Gene Ther. 2002, 2:211-226.
2. Duong C.P., Westwood J.A., Berry L.J., Darcy P.K., Kershaw M.H. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 2011, 3:33-48.
3. Eshhar Z. Adoptive cancer immunotherapy using genetically engineered designer T-cells: first steps into the clinic. Curr. Opin. Mol. Ther. 2010, 12:55-63.
4. Hombach A., Abken H. Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. Cancer Immunol. Immunother. 2006, 56:731-737.
5. Sadelain M., Brentjens R., Rivière I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 2009, 21:215-223.
6. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
7. Vincke C., Loris R., Saerens D., Martinez-Rodriguez S., Muyldermans S., Conrath K. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 2009, 284:3273-3284.
8. Ulrichts H., Silence K., Schoolmeester A., de Jaegere P., Rossenu S., Roodt J., Priem S., Lauwereys M., Casteels P., Van Bockstaele F., Verschueren K., Stanssens P., Baumeister J., Holz J.B. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011, 118:757-765.
9. Van Bockstaele F., Holz J.B., Revets H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig. Drugs 2009, 10:1212-1224.
10. Rahbarizadeh F., Rasaee M.J., Forouzandeh-Moghadam M., Allameh A.A. High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli. Protein Expr. Purif. 2005, 44:32-38.
11. Taylor-Papadimitriou J., Burchell J., Miles D.W., Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta 1999, 1455:301-313.
12. Taylor-Papadimitriou J., Burchell J.M., Plunkett T., Graham R., Correa I., Miles D., Smith M. MUC1 and the immunobiology of cancer. J. Mammary Gland Biol. Neoplasia 2002, 7:209-221.
13. Chu P.G., Schwarz R.E., Lau S.K., Yen Y., Weiss L.M. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am. J. Surg. Pathol. 2005, 29:359-367.
14. Wilkie S., Picco G., Foster J., Davies D.M., Julien S., Cooper L., Arif S., Mather S.J., Taylor-Papadimitriou J., Burchell J.M., Maher J. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 2008, 180:4901-4909.
15. Baxevanis C., Papamichail M. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes. Cancer Immunol. Immunother. 2004, 53:893-903.
16. Finney H.M., Lawson A.D., Bebbington C.R., Weir A.N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 1998, 161:2791-2797.
17. Michaelsen T.E., Frangione B., Franklin E.C. Primary structure of the "hingequot; region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit. J. Biol. Chem. 1977, 252:883-889.
18. Tischenko V.M. Effect of hinge region state on interaction of human IgG3 with the complement system. Biochemistry (Mosc) 2001, 66:1352-1355.
19. Kershaw M.H., Teng M.W., Smyth M.J., Darcy P.K. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 2005, 5:928-940.
20. Ishikawa Y., Tanaka N., Murakami K., Uchiyama T., Kumaki S., Tsuchiya S., Kugoh H., Oshimura M., Calos M.P., Sugamura K. Phage φC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J. Gene Med. 2006, 8:646-653.
21. Calos M.P. The phiC31 integrase system for gene therapy. Curr. Gene Ther. 2006, 6:633-645.
22. Chalberg T.W., Portlock J.L., Olivares E.C., Thyagarajan B., Kirby P.J., Hillman R.T., Hoelters J., Calos M.P. Integration specificity of phage phiC31 integrase in the human genome. J. Mol. Biol. 2006, 357:28-48.
23. Andreas S., Schwenk F., Kuter-Luks B., Faust N., Kuhn R. Enhanced efficiency through nuclear localization signal fusion on phage PhiC31-integrase: activity comparison with Cre and FLPe recombinase in mammalian cells. Nucleic Acids Res. 2002, 30:2299-2306.
24. Bakhtiari S.H., Rahbarizadeh F., Hasannia S., Ahmadvand D., Iri-Sofla F.J., Rasaee M.J. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function. Hybridoma (Larchmt) 2009, 28:85-92.
25. Rahbarizadeh F., Rasaee M.J., Forouzandeh M., Allameh A.A. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol. Immunol. 2006, 43:426-435.
26. Ortiz-Urda S., Thyagarajan B., Keene D.R., Lin Q., Fang M., Calos M.P., Khavari P.A. Stable nonviral genetic correction of inherited human skin disease. Nat. Med. 2002, 8:1166-1170.
27. Maucksch C., Aneja M.K., Hennen E., Bohla A., Hoffmann F., Elfinger M., Rosenecker J., Rudolph C. Cell type differences in activity of the Streptomyces bacteriophage C31 integrase. Nucleic Acids Res. 2008, 36:5462-5471.
28. Nasiri H., Forouzandeh M., Rasaee M.J., Rahbarizadeh F. Modified salting-out method: high-yield, high-quality genomic DNA extraction from whole blood using laundry detergent. J. Clin. Lab. Anal. 2005, 19:229-232.
29. Keravala A., Portlock J.L., Nash J.A., Vitrant D.G., Robbins P.D., Calos M.P. PhiC31 integrase mediates integration in cultured synovial cells and enhances gene expression in rabbit joints. J. Gene Med. 2006, 8:1008-1017.
30. Ahmadvand D., Rahbarizadeh F., Vishteh V.K. High-expression of monoclonal nanobodies used in the preparation of HRP-conjugated second antibody. Hybridoma (Larchmt) 2008, 27:269-276.
31. Ahmadvand D., Rasaee M.J., Rahbarizadeh F., Kontermann R.E., Sheikholislami F. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol. Immunol. 2009, 46:1814-1823.
32. Gross G., Gorochov G., Waks T., Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant. Proc. 1989, 21:127-130.
33. Morris E., Hart D., Gao L., Tsallios A., Xue S., Stauss H. Generation of tumor-specific T-cell therapies. Blood Rev. 2006, 20:61-69.
34. Banta S., Megeed Z., Casali M., Rege K., Yarmush M.L. Engineering protein and peptide building blocks for nanotechnology. J. Nanosci. Nanotechnol. 2007, 7:387-401.
35. Saerens D., Ghassabeh G.H., Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 2008, 8:600-608.
36. Weijtens M.E., Hart E.H., Bolhuis R.L. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene Ther. 2000, 7:35-42.
37. Sauer B., Henderson N. Targeted insertion of exogenous DNA into the eukaryotic genome by the Cre recombinase. New Biol. 1990, 2:441-449.
38. Bertoni C., Jarrahian S., Wheeler T.M., Li Y., Olivares E.C., Calos M.P., Rando T.A. Enhancement of plasmid-mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:419-424.
39. Groth A.C., Olivares E.C., Thyagarajan B., Calos M.P. A phage integrase directs efficient site-specific integration in human cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5995-6000.
40. Quenneville S.P., Chapdelaine P., Rousseau J., Beaulieu J., Caron N.J., Skuk D., Mills P., Olivares E.C., Calos M.P., Tremblay J.P. Nucleofection of muscle-derived stem cells and myoblasts with phiC31 integrase: stable expression of a full-length-dystrophin fusion gene by human myoblasts. Mol. Ther. 2004, 10:679-687.
41. Ko Y.G., Kang Y.S., Park H., Seol W., Kim J., Kim T., Park H.S., Choi E.J., Kim S. Apoptosis signal-regulating kinase 1 controls the proapoptotic function of death-associated protein (Daxx) in the cytoplasm. J. Biol. Chem. 2001, 276:39103-39106.
42. Chen J.Z., Ji C.N., Xu G.L., Pang R.Y., Yao J.H., Zhu H.Z., Xue J.L., Jia W. DAXX interacts with phage PhiC31 integrase and inhibits recombination. Nucleic Acids Res. 2006, 34:6298-6304.
43. Dingwall C., Laskey R.A. Nuclear targeting sequences-a consensus?. Trends Biochem. Sci. 1991, 16:478-481.
44. Le Y., Gagneten S., Tombaccini D., Bethke B., Sauer B. Nuclear targeting determinants of the phage P1 cre DNA recombinase. Nucleic Acids Res. 1999, 27:4703-4709.
45. Saito T., Yokosuka T., Hashimoto-Tane A. Dynamic regulation of T cell activation and co-stimulation through TCR-microclusters. FEBS Lett. 2010, 584:4865-4871.